Sky Solar Holdings, an independent power producer with solar assets mainly in Greece and Japan, announced terms for its IPO on Wednesday. The Hong Kong-based company plans to raise $138 million by offering 12.5 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Sky Solar Holdings would command a fully diluted market value of $604 million.
Sky Solar operates solar parks producing 52 MW of electricity in Greece (44% capacity), Japan (36%), the Czech Republic (11%) and Bulgaria (7%). Most of its power purchase agreements fix the price of ...more
S1 Biopharma, a biotech developing a combined therapy of existing drugs for female sexual dysfunction, announced terms for its IPO on Wednesday. The New York, NY-based company plans to raise $36 million by offering 2.8 million shares at a price range of $12 to $14. At the midpoint of the proposed range, S1 Biopharma would command a fully diluted market value of $132 million.
S1 Biopharma is entering Phase 2b trials for its lead candidate, which targets female hypoactive sexual desire disorder (HSDD), a lack or absence of sexual desire causing marked distress and interpersonal ...more
Tobira Therapeutics, a biotech developing an immunotherapy treatment for liver disease (NASH) and HIV, revived plans for its upcoming IPO in an amendment filed on Tuesday with blank terms and fewer underwriters. The company originally planned to raise $60 million in late July and command a fully diluted market value of $150 million but postponed its IPO citing market conditions.
Tobira is enrolling patients in Phase 2b trials for its once-daily pill for nonalcoholic steatohepatitis, or NASH. It expects that the growing rate of obesity in the US will only further ...more
DBV Technologies, a French biotech developing immunotherapy patches that treat food allergies, raised $93 million by offering 4.3 million ADSs at $21.64, below its $23 proposed offer price. DBV Technologies will list on the NASDAQ under the symbol [DBVT]. The Bagneux, France-based company is currently listed on the Euronext Paris under the symbol DBV. Citi, Leerink Partners and Bryan, Garnier & Co acted as joint bookrunners on the deal....more